Predict your next investment

HEALTHCARE | Drug Development
kringle-pharma.com

See what CB Insights has to offer

Founded Year

2001

Stage

IPO | IPO

Total Raised

$46.32M

Date of IPO

12/28/2020

Market Cap

3.15B

About Kringle Pharma

Kringle Pharma is a clinical-stage biopharmaceutical company that engages in the research, development, and commercialization of HGF protein medicines for patients suffering from incurable diseases, acute spinal cord injuries, ALS, acute kidney injuries, and more.

Kringle Pharma Headquarter Location

207 Saito Bio Incubator 7-7-15 Saitoasagi, Ibaraki

Osaka, 567-0085,

Japan

Latest Kringle Pharma News

Spinal Cord Injury Pipeline Insight Report 2021: Approx 35 Companies & 35 Pipeline Drugs - ResearchAndMarkets.com

Jun 10, 2021

June 10, 2021 05:07 AM Eastern Daylight Time This "Spinal cord injury - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal cord injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Spinal cord injury Emerging Drugs Chapters This segment of the Spinal cord injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Spinal cord injury Emerging Drugs KP-100IT: Kringle Pharma HGF (KP-100IT) protects neurons and promotes the extension of axons, it can be developed as a potential treatment for spinal cord injury. It is currently in Phase III for spinal cord injury. It is being developed by Kringle Pharma. ES135: Eusol Biotech ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. With its effect to promote neurite outgrowth, ES135 can be applied to the medical use of repairing neuron function. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. A multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury is on-going. Elezanumab: AbbVie Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor thus potentially promoting neuroregeneration. It is currently in phase 2 stage of development. Sovateltide: Pharmazz Sovateltide is an endothelin B (ETB) receptor agonist. Activation of ETB receptors with PMZ-1620 produces neurovascular repair and remodeling or neuroregeneration. It is currently in Phase 2 for acute spinal cord injury. FAB117-HC: Histocell FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2. The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), and improved with Histocell's proprietary technology. Currently in phase 1/2 of development stage for spinal cord injuries. NEU-2000: AmKor Pharma NMDA antagonism and antioxidant action of Nelonemdaz (NEU-2000) would prevent the damages of brain and spinal cord cells induced by Traumatic Brain Injury (TBI) & Traumatic Spinal Cord Injury (TSI). It is currently in Phase I for spinal cord injury. Nelonemdaz is designed as the first multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of neuronal death in stroke and traumatic brain/spinal cord injury. Spinal cord injury: Therapeutic Assessment This segment of the report provides insights about the different Spinal cord injury drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Spinal cord injury There are approx. 35+ key companies which are developing the therapies for Spinal cord injury. The companies which have their Spinal cord injury drug candidates in the most advanced stage, i.e. phase III include, Kringle Pharma. Phases Late stage products (Phase III) Mid-stage products (Phase II)

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kringle Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kringle Pharma is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

14,139 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Kringle Pharma Patents

Kringle Pharma has filed 15 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Neurological disorders
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/28/2018

7/7/2020

Transcription factors, Neurological disorders, Rare diseases, Proteins, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/28/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/7/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Neurological disorders, Rare diseases, Proteins, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Kringle Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kringle Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.